Rubius Therapeutics, Inc. Balance Sheet

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated balance sheets

In millions of USD; shares in millions, except per-share amounts

	Q4 FY2022 As of Dec 31, 2022	Q3 FY2022 As of Sep 30, 2022	Q2 FY2022 As of Jun 30, 2022	Q1 FY2022 As of Mar 31, 2022	Q4 FY2021 As of Dec 31, 2021	Q3 FY2021 As of Sep 30, 2021	Q2 FY2021 As of Jun 30, 2021	Q1 FY2021 As of Mar 31, 2021	Q4 FY2020 As of Dec 31, 2020	Q3 FY2020 As of Sep 30, 2020	Q2 FY2020 As of Jun 30, 2020	Q1 FY2020 As of Mar 31, 2020	Q4 FY2019 As of Dec 31, 2019	Q3 FY2019 As of Sep 30, 2019	Q2 FY2019 As of Jun 30, 2019	Q1 FY2019 As of Mar 31, 2019	Q4 FY2018 As of Dec 31, 2018	Q3 FY2018 As of Sep 30, 2018	Q2 FY2018 As of Jun 30, 2018
Assets
Current assets:
Cash and cash equivalents
Marketable securities
Investments
Assets held for sale
Prepaid expenses and other current assets
Restricted cash
Total current assets

Operating lease, right-of-use-asset
Property, plant and equipment, net
Restricted cash
Deferred offering costs
Other assets
Total assets

Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable
Accrued expenses and other current liabilities
Current portion of long-term debt, net of discount
Operating lease liabilities
Total current liabilities
Long-term debt, net of discount
Deferred rent
Preferred stock warrant liability
Liability for early exercise of stock options and restricted stock
Other long-term liabilities
Operating lease liabilities, net of current portion
Lease financing obligation
Total liabilities
Convertible preferred stock (Series A, B and C), $0.001 par value; no shares and 44,070,808 shares authorized at December 31, 2018 and 2017, respectively; no shares and 43,933,006 shares issued and outstanding at December 31, 2018 and 2017, respectively
Stockholders' equity:
Preferred stock, $0.001 par value; 10,000,000 shares authorized at December 31, 2022 and December 31, 2021; no shares issued or outstanding at December 31, 2022 and December 31, 2021
Common stock, $0.001 par value; 300,000,000 and 150,000,000 shares authorized at December 31, 2022 and December 31, 2021, respectively; 90,387,732 and 90,063,770 shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively
Additional paid-in capital
Accumulated other comprehensive loss
Accumulated deficit
Total stockholders' equity
Total liabilities and stockholders' equity

Common stock, share authorized (in shares)

Comments